Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues). In 2024, 71% of the company's revenues came from the United States.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | 2025-10-30 19:59:49 | 45.31 | -0.31 | -0.68 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | 0000014272 | BRISTOL MYERS SQUIBB CO | US1101221083 | HLYYNH7UQUORYSJQCN42 | 220790350 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | DE | ROUTE 206 AND PROVINCE LINE ROAD | PRINCETON | NJ | 08543 | UNITED STATES | US | 6092524621 | ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543 | ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543 | — | Pharmaceuticals | 1887 | Chris Boerner | 34,100 | https://www.bms.com | 84,156,423,913 | 2,900,000,000 | 2,035,435,838 | Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues). In 2024, 71% of the company's revenues came from the United States. | 2025-10-30 12:12:34 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 84,156,423,913 | -49,342,465,607 | -36.961 | 2,029,312,023 | 7,118,612 | 0.352 |
| 2023 | 133,498,889,520 | -30,802,163,319 | -18.7474 | 2,022,193,411 | -76,582,567 | -3.6489 |
| 2022 | 164,301,052,839 | 15,917,897,193 | 10.7276 | 2,098,775,978 | -80,936,842 | -3.7132 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Samit Hirawat | Chief Medical Officer, EVP | 2024 | 1,115,000 | 0 | 5,617,762 | 1,564,234 | 289,018 | 8,586,014 |
| Sandra Leungevp And | General Counsel | 2024 | 1,150,000 | 0 | 3,959,204 | 1,613,335 | 289,251 | 7,011,790 |
| Christopher S. Boerner | Chair, Chief Executive Officer | 2024 | 1,536,538 | 0 | 13,643,063 | 3,235,581 | 372,436 | 18,787,618 |
| David V. Elkinsevp And | Chief Financial Officer | 2024 | 1,115,000 | 0 | 5,778,244 | 1,564,234 | 250,093 | 8,707,571 |
| Samit Hirawat | Chief Medical Officer, EVP | 2023 | 1,103,781 | 0 | 3,616,394 | 1,234,117 | 279,335 | 6,233,627 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 34,100 |
| 2023 | 34,100 |
| 2022 | 34,300 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 48,300,000,000 | 45,006,000,000 | 46,159,000,000 |
| Cost Of Revenue | 13,968,000,000 | 10,693,000,000 | 10,137,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 11,159,000,000 | 9,299,000,000 | 9,509,000,000 |
| General And Administrative Expenses | 8,414,000,000 | 7,772,000,000 | 7,814,000,000 |
| Operating Expenses | 56,679,000,000 | 36,566,000,000 | 38,446,000,000 |
| Operating Income | — | — | — |
| Net Income | -8,948,000,000 | 8,025,000,000 | 6,327,000,000 |
| Earnings Per Share Basic | -4.41 | 3.88 | 2.97 |
| Earnings Per Share Diluted | -4.41 | 3.86 | 2.95 |
| Weighted Average Shares Outstanding Basic | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 |
| Weighted Average Shares Outstanding Diluted | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 10,346,000,000 | 11,464,000,000 | 9,123,000,000 |
| Marketable Securities Current | 513,000,000 | 816,000,000 | 130,000,000 |
| Accounts Receivable | 10,747,000,000 | 10,921,000,000 | 9,886,000,000 |
| Inventories | 2,557,000,000 | 2,662,000,000 | 2,339,000,000 |
| Non Trade Receivables | 1,735,000,000 | 2,039,000,000 | 1,735,000,000 |
| Other Assets Current | 5,617,000,000 | 5,907,000,000 | 5,795,000,000 |
| Total Assets Current | 29,780,000,000 | 31,770,000,000 | 27,273,000,000 |
| Marketable Securities Non Current | 320,000,000 | 364,000,000 | — |
| Property Plant And Equipment | 7,136,000,000 | 6,646,000,000 | 6,255,000,000 |
| Other Assets Non Current | 6,105,000,000 | 5,370,000,000 | 4,940,000,000 |
| Total Assets Non Current | 62,823,000,000 | 63,389,000,000 | 69,547,000,000 |
| Total Assets | 92,603,000,000 | 95,159,000,000 | 96,820,000,000 |
| Accounts Payable | 3,602,000,000 | 3,259,000,000 | 3,040,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 2,046,000,000 | 3,119,000,000 | 4,264,000,000 |
| Other Liabilities Current | 18,126,000,000 | 15,884,000,000 | 14,586,000,000 |
| Total Liabilities Current | 23,774,000,000 | 22,262,000,000 | 21,890,000,000 |
| Long Term Debt | 49,431,000,000 | 39,526,000,000 | 38,953,000,000 |
| Other Liabilities Non Current | 4,469,000,000 | 6,421,000,000 | 6,590,000,000 |
| Total Liabilities Non Current | 52,441,000,000 | 43,412,000,000 | 43,812,000,000 |
| Total Liabilities | 76,215,000,000 | 65,674,000,000 | 65,702,000,000 |
| Common Stock | 292,000,000 | 292,000,000 | 292,000,000 |
| Retained Earnings | 14,912,000,000 | 28,766,000,000 | 25,503,000,000 |
| Accumulated Other Comprehensive Income | -1,238,000,000 | -1,546,000,000 | -1,281,000,000 |
| Total Shareholders Equity | 16,335,000,000 | 29,430,000,000 | 31,061,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 9,600,000,000 | 9,760,000,000 | 10,276,000,000 |
| Share Based Compensation Expense | 507,000,000 | 518,000,000 | 457,000,000 |
| Other Non Cash Income Expense | -94,000,000 | -308,000,000 | -232,000,000 |
| Change In Accounts Receivable | -264,000,000 | 995,000,000 | 663,000,000 |
| Change In Inventories | 486,000,000 | 751,000,000 | 69,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 184,000,000 | 198,000,000 | 109,000,000 |
| Change In Other Liabilities | -624,000,000 | 667,000,000 | 610,000,000 |
| Cash From Operating Activities | 15,190,000,000 | 13,860,000,000 | 13,066,000,000 |
| Purchases Of Marketable Securities | 769,000,000 | 1,774,000,000 | 3,592,000,000 |
| Sales Of Marketable Securities | 1,122,000,000 | 733,000,000 | 6,411,000,000 |
| Acquisition Of Property Plant And Equipment | 1,248,000,000 | 1,209,000,000 | 1,118,000,000 |
| Acquisition Of Business | 21,821,000,000 | 1,169,000,000 | 4,286,000,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -21,352,000,000 | -2,295,000,000 | -1,062,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 4,863,000,000 | 4,744,000,000 | 4,634,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 0 | 5,155,000,000 | 3,000,000,000 |
| Issuance Of Long Term Debt | 12,883,000,000 | 4,455,000,000 | 5,926,000,000 |
| Repayment Of Long Term Debt | 2,873,000,000 | 3,879,000,000 | 11,431,000,000 |
| Other Financing Activities | — | 27,000,000 | 984,000,000 |
| Cash From Financing Activities | 5,127,000,000 | -9,416,000,000 | -16,962,000,000 |
| Change In Cash | -1,172,000,000 | 2,194,000,000 | -4,991,000,000 |
| Cash At End Of Period | 10,346,000,000 | 11,464,000,000 | 9,123,000,000 |
| Income Taxes Paid | 3,900,000,000 | 4,300,000,000 | 5,400,000,000 |
| Interest Paid | 1,800,000,000 | 1,200,000,000 | 1,400,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -4.41 | 3.88 | 2.97 |
| Price To Earnings Ratio | -12.8254 | 13.2242 | 24.2256 |
| Earnings Growth Rate | -213.6598 | 30.6397 | -5.7143 |
| Price Earnings To Growth Ratio | 0.06 | 0.4316 | -4.2395 |
| Book Value Per Share | 8.0849 | 14.2508 | 14.6094 |
| Price To Book Ratio | 6.9958 | 3.6005 | 4.9249 |
| Ebitda | 6,499,000,000 | 23,251,000,000 | 23,235,000,000 |
| Enterprise Value | 155,778,120,000 | 137,341,390,000 | 187,347,500,000 |
| Dividend Yield | 0.0424 | 0.0447 | 0.0302 |
| Dividend Payout Ratio | -0.5435 | 0.5912 | 0.7324 |
| Debt To Equity Ratio | 3.1513 | 1.449 | 1.3914 |
| Capital Expenditures | 10,090,000,000 | 10,151,000,000 | 10,482,000,000 |
| Free Cash Flow | 5,100,000,000 | 3,709,000,000 | 2,584,000,000 |
| Return On Equity | -0.5478 | 0.2727 | 0.2037 |
| One Year Beta | 0.1352 | 0.439 | 0.2868 |
| Three Year Beta | 0.2814 | 0.3207 | 0.4955 |
| Five Year Beta | 0.4631 | 0.52 | 0.5519 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Gallman Cari | EVP, General Counsel | 2025-10-02 | 4,558 | A | 13,398 |
| Gallman Cari | EVP, General Counsel | 2025-10-02 | 2,332 | D | 11,066 |
| Gallman Cari | EVP, General Counsel | 2025-10-02 | 4,558 | D | 4,559 |
| Arduini Peter J | Director | 2025-09-30 | 748 | A | 64,620 |
| McMullen Michael R. | Director | 2025-09-30 | 776 | A | 10,076 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H Tuberville | Senator | 2025-05-15 | Sale (Full) | 2025-04-15 | Self | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-05-15 | Purchase | 2024-04-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-05-15 | Sale (Full) | 2024-04-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-02-14 | Sale (Partial) | 2024-01-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2023-12-15 | Sale (Full) | 2023-11-16 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-09-12 | OR04 | Purchase | 2024-10-29 | Spouse | $1,001 - $15,000 |
| Julie Johnson | 2025-09-11 | TX32 | Sale (Partial) | 2025-08-14 | Joint | $1,001 - $15,000 |
| Virginia Foxx | 2025-07-03 | NC05 | Sale | 2025-06-24 | — | $1,001 - $15,000 |
| Jefferson Shreve | 2025-06-22 | IN06 | Sale | 2025-05-12 | — | $15,001 - $50,000 |
| Julie Johnson | 2025-05-14 | TX32 | Sale | 2025-04-01 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Rossmore Private Capital | 2025-09-30 | 749,607 | 16,621 | 45.1 |
| Envestnet Portfolio Solutions, Inc. | 2025-09-30 | 4,493,623 | 99,637 | 45.0999 |
| JENNISON ASSOCIATES LLC | 2025-09-30 | 980,158 | 21,733 | 45.1 |
| HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC | 2025-09-30 | 639,000 | 14,094 | 45.3384 |
| Gibbs Wealth Management | 2025-09-30 | 676,760 | 15,006 | 45.0993 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SHELTON FUNDS | 2025-08-31 | K Shares | EQTKX | -390 | -11,700 | -0.0012 |
| SHELTON FUNDS | 2025-08-31 | K Shares | EQTKX | 157,200 | 7,416,696 | 0.7517 |
| SHELTON FUNDS | 2025-08-31 | Investor Shares | EQTIX | -390 | -11,700 | -0.0012 |
| SHELTON FUNDS | 2025-08-31 | Investor Shares | EQTIX | 157,200 | 7,416,696 | 0.7517 |
| SHELTON FUNDS | 2025-08-31 | K Shares | SPXKX | 11,029 | 520,348.22 | 0.1733 |